Lenvima and Tumor pain - a phase IV clinical study of FDA data

Summary:

Tumor pain is reported as a side effect among people who take Lenvima (lenvatinib mesylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zofran, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Tumor pain when taking Lenvima. It is created by eHealthMe based on reports of 21,107 people who have side effects when taking Lenvima from the FDA, and is updated regularly.

What is Lenvima?

Lenvima has active ingredients of lenvatinib mesylate. eHealthMe is studying from 21,113 Lenvima users. Check the latest studies of Lenvima.

What is Tumor pain?

Tumor pain is found to be associated with 214 drugs and 285 conditions by eHealthMe. Check the latest studies of Tumor pain.

On Jul, 29, 2026

21,107 people reported to have side effects when taking Lenvima.
Among them, 29 people (0.14%) have Tumor pain.

Among these 29 people:

How long have people been on Lenvima when they have Tumor pain? *

What is the gender of people who have Tumor pain when taking Lenvima? *

female: 48.28 %
male: 51.72 %

What is the age of people who have Tumor pain when taking Lenvima? *

What are other drugs people take besides Lenvima? *

Zofran: 8 people, 27.59%
Keytruda: 6 people, 20.69%
Afinitor: 5 people, 17.24%
Flomax: 5 people, 17.24%
Cabometyx: 4 people, 13.79%
Oxycodone: 3 people, 10.34%
Diovan: 3 people, 10.34%
Ondansetron Hydrochloride: 3 people, 10.34%
Pantoprazole: 2 people, 6.90%
Everolimus: 2 people, 6.90%

What are other side effects people have besides Tumor pain? *

Diarrhea: 17 people, 58.62%
High Blood Pressure: 15 people, 51.72%
Fatigue (feeling of tiredness): 15 people, 51.72%
Nausea (feeling of having an urge to vomit): 13 people, 44.83%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 13 people, 44.83%
Nausea And Vomiting: 11 people, 37.93%
Weight Decreased: 9 people, 31.03%
Weakness: 8 people, 27.59%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 24.14%
Hypotension (abnormally low blood pressure): 5 people, 17.24%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 10 people, 34.48%
Hepatocellular Carcinoma (liver cancer): 7 people, 24.14%
Endometrial Cancer: 7 people, 24.14%
Thyroid Cancer: 1 person, 3.45%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 3.45%
Renal Neoplasm (kidney tumour): 1 person, 3.45%
Metastases To Lung (cancer spreads to lung): 1 person, 3.45%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 3.45%
High Blood Pressure: 1 person, 3.45%
Benign Renal Neoplasm (benign (non-cancerous) tumours of the kidney): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Lenvima and have Tumor pain?

- Check whether Tumor pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lenvima:

Lenvima (21,113 reports)

Tumor pain treatments and more:

Tumor pain (3,414 reports)

Browse all side effects of Lenvima:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor pain:

Tumor pain (214 drugs)

Browse all the conditions that are associated with Tumor pain:

Tumor pain (285 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenvatinib mesylate (the active ingredients of Lenvima) and Lenvima (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.